Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+primary resistant or relapsed acute myeloid leukemia

被引：58

作者：

Tsimberidou, A ^{[1
]}

Cortes, J ^{[1
]}

Thomas, D ^{[1
]}

Garcia-Manero, G ^{[1
]}

Verstovsek, S ^{[1
]}

Faderl, S ^{[1
]}

Albitar, M ^{[1
]}

Kantarjian, H ^{[1
]}

Estey, E ^{[1
]}

Giles, FJ ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

LEUKEMIA RESEARCH | 2003年 / 27卷 / 10期

关键词：

Mylotarg (TM); fludarabine; cytarabine; cyclosporine; gemtuzumab ozogamicin; acute myelogenous leukemia; refractory;

D O I：

10.1016/S0145-2126(03)00022-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Clinical resistance to gemtuzumab ozogamicin (Mylotarg(TM)) in acute myeloid leukemia (AML) is associated with blast multidrug resistance (MDR) phenotype. A Phase II study of Mylotarg, fludarabine, ara-C and the MDR-modifier, cyclosporine (CSA) (MFAC) was conducted in 32 patients with primary resistant (11, 34%) or relapsed (21, 66%) AML. Nine (28%) patients obtained complete remission (CR), two (6%) CR with incomplete platelet recovery. Overall median survival was 5.3 months, 12-month survival rate 19%. Fourteen patients (44%) developed grade 3/4 hyperbilirubinemia; six (18%) grade 3/4 hepatic transaminitis; three (9%) hepatic veno-occlusive disease (VOD). CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML. (C) 2003 Elsevier Science Ltd. All rights reserved.

引用

页码：893 / 897

页数：5

共 28 条

[1]

Amadori S, 2001, BLOOD, V98, p587A

[2]

Bross PF, 2001, CLIN CANCER RES, V7, P1490

[3]

DeAngelo D, 2001, BLOOD, V98, p199B

[4] FLUDARABINE AND ARABINOSYLCYTOSINE THERAPY OF REFRACTORY AND RELAPSED ACUTE MYELOGENOUS LEUKEMIA [J].

ESTEY, E ;

PLUNKETT, W ;

GANDHI, V ;

RIOS, MB ;

KANTARJIAN, H ;

KEATING, MJ .

LEUKEMIA & LYMPHOMA, 1993, 9 (4-5) :343-350

[5] A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia [J].

Estey, E ;

Kornblau, S ;

Pierce, S ;

Kantarjian, H ;

Beran, M ;

Keating, M .

BLOOD, 1996, 88 (02) :756-756

[6] Experience with gemtuzumab ozogamycin ("mylotarg"), and all-trans retinoic acid in untreated acute promyelocytic leukemia [J].

Estey, EH ;

Giles, FJ ;

Beran, M ;

O'Brien, S ;

Pierce, SA ;

Faderl, SH ;

Cortes, JE ;

Kantarjian, HM .

BLOOD, 2002, 99 (11) :4222-4224

[7] Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside [J].

Estey, EH ;

Thall, PF ;

Giles, FJ ;

Wang, XM ;

Cortes, JE ;

Beran, M ;

Pierce, SA ;

Thomas, DA ;

Kantarjian, HM .

BLOOD, 2002, 99 (12) :4343-4349

[8] Comparison of idarubicin plus ara-C-, fludarabine plus ara-C-, and topotecan plus ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts [J].

Estey, EH ;

Thall, PF ;

Cortes, JE ;

Giles, FJ ;

O'Brien, S ;

Pierce, SA ;

Wang, XM ;

Kantarjian, HM ;

Beran, M .

BLOOD, 2001, 98 (13) :3575-3583

[9]

Giles F, 2002, HAEMATOLOGICA, V87, P1114

[10]

Giles FJ, 2001, CANCER-AM CANCER SOC, V92, P406, DOI 10.1002/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO

← 1 2 3 →